Reams G, Lau A, Knaus V, Bauer J H
Department of Medicine, University of Missouri, Columbia 65212.
J Clin Pharmacol. 1991 May;31(5):468-72. doi: 10.1002/j.1552-4604.1991.tb01905.x.
Twelve hypertensive patients with moderately severe renal dysfunction were entered into a protocol to assess the blood pressure and renal effects of the sustained release calcium antagonist, nifedipine GITS (30-180 mg/d given once a day) administered for 5 weeks. Nifedipine GITS monotherapy effectively lowered blood pressure in 50% of the patients. Glomerular filtration rate and effective renal plasma flow were increased 18% and 20%, respectively. The filtration fraction and urinary protein excretion remained unchanged. Changes that were observed in renal function were independent of the blood pressure responses of the patients; there was no correlation between the systemic and renal effect of nifedipine GITS monotherapy. Patients who had a poor systemic blood pressure response exhibited an increase in glomerular filtration rate (+11%) but had a decrease in effective renal plasma flow (-6%); patients who achieved a goal blood pressure response showed increases in both glomerular filtration rate (+35%) and effective renal plasma flow (+40%). These results show that nifedipine GITS monotherapy has the potential to improve renal function abnormalities that are encountered in hypertensive patients with renal disease; the improvement in renal function may be independent of their effect on systemic blood pressure.
12名患有中度严重肾功能不全的高血压患者参与了一项方案,以评估持续释放钙拮抗剂硝苯地平控释片(每日一次,给予30 - 180毫克/天)治疗5周对血压和肾脏的影响。硝苯地平控释片单药治疗使50%的患者血压有效降低。肾小球滤过率和有效肾血浆流量分别增加了18%和20%。滤过分数和尿蛋白排泄保持不变。观察到的肾功能变化与患者的血压反应无关;硝苯地平控释片单药治疗的全身和肾脏效应之间没有相关性。全身血压反应不佳的患者肾小球滤过率增加(+11%),但有效肾血浆流量减少(-6%);达到目标血压反应的患者肾小球滤过率(+35%)和有效肾血浆流量(+40%)均增加。这些结果表明,硝苯地平控释片单药治疗有可能改善肾病高血压患者出现的肾功能异常;肾功能的改善可能与其对全身血压的影响无关。